Direct aid of approximately MSEK 4.3 or € 419,500 granted to Aegirbio AB’s Eurostar application
Aegirbio's application for financial aid from Eurostar concerning the project “A cost-effective and broadly applicable mimetope based diagnostic platform for high-impact pandemics” has been granted, with a total project budget of € 1,442,500.Aegirbio's share of the project is approximately MSEK 8.6, and the German partner Lixonex GmbH has the remaining share. Aegirbio will allocate resources to bear half of its own expenses. The remainder, approximately MSEK 4.3, will be received through Vinnova as a direct cash grant. The project aims to develop a new platform for point-of-care (POC)